Clinical Trial Update: A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of mRNA-1608, Moderna's HSV-2 therapeutic vaccine, in healthy adults with recurrent genital herpes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Herpes

Drugs mentioned

• mRNA-1608

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Genital Herpes | Phase 1, Phase 2 | Status: COMPLETED